The Latest Cardiac and Vascular News
Patented SelectFlex™ Technology allows operators to achieve the ideal balance of trackability and support on demand to navigate complex neurovasculature System enables biaxial approach, regardless of access site, to eliminate complexity and cost of conventional configurations FREMONT,…
MIAMI, Dec. 27, 2024 /PRNewswire/ — Navigantis Inc. announced today the first successful neurovascular clinical cases performed with its VASCO interventional robotic platform for patients suffering from neurovascular disorders. “This achievement marks an important milestone in our…
TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today’s standard of care – saving lives and reducing disability Following the Phase 1 safety study, TargED intends to further develop TGD001 in patients with AIS and iTTP…
STAMFORD, Conn., Dec. 17, 2024 /PRNewswire/ — Neuvotion, Inc. is an early-stage medical device company developing AI-driven neuromodulation technologies and products for use in the neurorehabilitation, brain-computer interface (BCI), and physical therapy markets. Today Neuvotion has…
MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) — RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida focused on improving the treatment success rate for acute ischemic stroke (AIS) announced that the United States Food and Drug Administration (FDA) agreed that RapidPulse can begin enrollment in an Investigational Device Exemption (IDE) study of its novel and precise cyclic aspiration system. This will allow U.S. and European patient enrollment in 2025 to commence in a study designed to demonstrate the RapidPulse patented method of precisely pulsed aspiration is safe and effective in the treatment of AIS. RapidPulse’s technology is a spin-out of Syntheon 2.0, LLC, an innovative medical device incubator with a long track record of successful exits.
BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) — Balt, Inc., a global technology leader in neurovascular devices, today announced the publication of The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma in the New England Journal of Medicine. The study shows that among patients with symptomatic chronic subdural hematoma (cSDH), adjunctive middle meningeal artery (MMA) embolization resulted in a lower risk of treatment failure than standard treatment alone, without resulting in an increased incidence of disabling stroke or death in the short term. STEM is the first randomized prospective IDE trial investigating embolization of the MMA for the treatment of cSDH.
Route 92 Medical announces EU and MDSAP certification for its neurovascular stroke-intervention-focused product portfolio.
NeuroVascular Quality Initiative Quality Outcomes Database (NVQI-QOD) Celebrates 25,000th Procedure Milestone FAIRFAX, Va.– The Society of NeuroInterventional Surgery’s (SNIS) Patient Safety Organization (PSO), in partnership with the NeuroPoint Alliance (NPA), is pleased to announce that the NVQI-QOD has recorded more than 25,000 procedures in the registry. This significant milestone underscores […]
CHILLICOTHE, Ohio, Nov. 19, 2024 /PRNewswire/ — When something doesn’t feel right, you need expert care that’s close to home. Adena Health understands this, and that is why the experts with the Adena Heart and Vascular Institute and Adena Orthopedic and Spine Institute strive to deliver…
RapidAI’s leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at the forefront of AI-based imaging solutions. SAN ANTONIO, Oct. 30, 2024 /PRNewswire/ — Recently Frost & Sullivan researched the…
